IDH1 and astrocytoma (excluding glioblastoma): Across 1000 cross-validation trials, 3.4% (N = 12) of IDH-wildtype glioblastomas and 2.3% (N = 6) of IDH-mutant astrocytomas were misclassified in at least 50% of trials (Fig. 4A).